New Delhi, May 03, 2014 –
Bayer AG (BAYN) is in exclusive talks to acquire Merck & Co.’s consumer business and is prepared to pay about $14 billion for the division, people with knowledge of the matter said.
An announcement is likely to come in the next few days, said the people, who asked not to be identified because the talks are private. While the two sides have agreed to a deal in principle, they are still working out details and haven’t formally reached an agreement, the people said. The terms would include cash and an exchange ofpharmaceutical assets, possibly structured as a joint venture, the people said.
A deal would strengthen Merck’s core drug business while helping Bayer to beef up its consumer-products line by adding brands including Claritin allergy relief. It would be similar to other recent pharmaceutical transactions, in which companies have sold weaker business lines and added to areas where they are more competitive.Bloomberg
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…